Values First Advisors Inc. Increases Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Values First Advisors Inc. raised its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 59.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,980 shares of the biopharmaceutical company’s stock after buying an additional 6,354 shares during the period. Values First Advisors Inc.’s holdings in Sage Therapeutics were worth $368,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in SAGE. RTW Investments LP bought a new stake in shares of Sage Therapeutics during the 3rd quarter valued at $105,976,000. Goldman Sachs Group Inc. grew its position in shares of Sage Therapeutics by 252.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,106,276 shares of the biopharmaceutical company’s stock valued at $35,733,000 after acquiring an additional 792,819 shares during the period. State Street Corp grew its position in shares of Sage Therapeutics by 30.8% during the 1st quarter. State Street Corp now owns 2,835,356 shares of the biopharmaceutical company’s stock valued at $93,850,000 after acquiring an additional 666,826 shares during the period. BlackRock Inc. grew its position in shares of Sage Therapeutics by 13.7% during the 3rd quarter. BlackRock Inc. now owns 4,822,063 shares of the biopharmaceutical company’s stock valued at $188,833,000 after acquiring an additional 580,250 shares during the period. Finally, Morgan Stanley grew its position in shares of Sage Therapeutics by 145.5% during the 3rd quarter. Morgan Stanley now owns 863,932 shares of the biopharmaceutical company’s stock valued at $17,780,000 after acquiring an additional 512,021 shares during the period. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SAGE. Royal Bank of Canada boosted their price objective on shares of Sage Therapeutics from $21.00 to $26.00 and gave the company a “sector perform” rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. upped their target price on shares of Sage Therapeutics from $24.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday. HC Wainwright upped their target price on shares of Sage Therapeutics from $25.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, February 15th. Stifel Nicolaus dropped their target price on shares of Sage Therapeutics from $22.00 to $20.00 and set a “hold” rating for the company in a report on Monday, December 18th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sage Therapeutics in a report on Tuesday, December 12th. They issued a “hold” rating and a $21.00 target price for the company. Fifteen investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $41.00.

Sage Therapeutics Trading Down 1.6 %

Shares of NASDAQ SAGE traded down $0.30 during midday trading on Thursday, reaching $18.74. The company had a trading volume of 1,004,673 shares, compared to its average volume of 963,600. The business’s 50-day simple moving average is $22.68 and its 200 day simple moving average is $21.40. The stock has a market cap of $1.13 billion, a P/E ratio of -2.07 and a beta of 0.87. Sage Therapeutics, Inc. has a 1 year low of $16.51 and a 1 year high of $59.99.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.28) by $0.73. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The company had revenue of $77.97 million during the quarter, compared to analysts’ expectations of $60.15 million. During the same quarter in the previous year, the company earned ($2.47) earnings per share. The firm’s revenue for the quarter was up 2621.5% on a year-over-year basis. Analysts predict that Sage Therapeutics, Inc. will post -6.06 earnings per share for the current year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.